| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 580.53 | 10.5% | 30.8% |
| Total Income | 599.53 | 7.3% | 25.5% |
| Expenditure | 485.16 | 9.5% | 35.9% |
| PBT | 123.94 | 7.1% | 2.7% |
| Net Profit | 95.13 | 11.6% | 3.6% |
| OPM | 25.34% | 1.53pp | 0.50pp |
| NPM | 15.87% | 0.61pp | 3.34pp |
| EPS | 9.38 | 10.5% | 3.5% |
Revenue Boom, Profit Lag — Can Poly Restore Growth?
Consolidated revenue surged 30.8% to ₹580.5 Cr, but PAT crawled 3.6% to ₹95.1 Cr — a 27-point gap driven by inventory reversal, acquisition drag, and cost headwinds. The call reveals a normalized EBITDA margin of 25.3%, but management's margin-recovery timeline now stretches into FY28–FY29.
₹95.1 Cr
+3.6% YoY
25.3%
normalized; acquisition drag embedded
27 pp
+30.8% vs +3.6% growth
22%
beating 20% guidance
On paper, Poly delivered a blowout quarter: ₹580.5 Cr in consolidated revenue, up 31% from a year ago. But look at the bottom line, and the picture inverts. PAT of ₹95.1 Cr eked out just 3.6% growth. That 27-point gap between revenue and profit growth is not accounting noise—it is the story of a quarter where scale masked margin trouble.
The margin collapse, explained
Three things clobbered profit. First, Q1 witnessed ₹200–₹300 Cr in inventory gains (from clearing backlog) that reversed entirely in Q2, erasing the cushion. Second, the acquisitions—PendraCare and Citieffe—are operating at 4–5% EBITDA margin, dragging consolidated performance. Third, raw-material costs and FX headwinds, despite 4–5% price hikes, are still biting. Gross margin expanded 111 bps to 70.1% on pricing and acquisition mix, but EBITDA margin tells the truth: 25.3% normalized—solid in isolation, but a comedown from the 27%–29% the standalone business would deliver clean.
Claims on the call vs. what holds up
Europe business organic growth 40% in Q2
Organic Q2 European revenue ~40%; driven by inventory normalization and 28–29 new customer adds in H1. Management notes opportunity set remains 'very large.'
Supported
Domestic business growing 22% in Q2, tracking 20% guidance
Domestic Q2 revenue ₹172 Cr, +22% YoY; H1 domestic ≈20%. On track with stated guidance.
Supported
Gross margin 70.1% in H1, expanding 111 bps YoY
H1 consolidated gross margin 70.1%, up 111 bps. Pricing and acquisition contribution offset FX and raw-material headwinds.
Supported
Renal business recovering well despite Chinese dumping
Q2 renal revenue ₹51 Cr, +20% YoY; anti-dumping case filed end-June, 4 months in pursuit. 'Few months' away from government action; single-use device mandate (DGHS Oct/Nov) expected tailwind.
Overstated (recovery contingent on relief)
PAT growth tracking revenue growth
PAT +3.6% YoY vs revenue +30.8%. Compressed by inventory reversal (Q1 gains lost), FX/raw-material costs, acquisition drag. Normalized EBITDA margin ~25.3%.
Contradicted
What changed on this call
Standalone EBITDA margin raised to 26–27.5% (from 25–27%)
International business inflection confirmed (Europe 40% organic, international 15% YoY in Q2)
Acquired business margin recovery extended to 3–5 years (vs. earlier implied near-term)
U.S. business now quantified: ₹15–25m over 3–5 years (from ₹7m current)
FX/raw-material headwind expected H2 FY27; normalization deferred
The street's view: FII exodus and drawdown context
The stock closed at ₹1620 on November 9, down 51.75% from its all-time high of ₹3357.8. It is below its 50-day average (₹1629.65) but above the 200-day (₹1544.38), leaving it in a narrow neutral band. RSI of 57.7 signals no oversold trigger. But the ownership picture is more telling: FII holdings have halved from 11.41% in FY26 Q1 to 5.57% in FY27 Q1—a 590 basis-point exodus—while DII has been steadily accumulating. This is a stock that foreign institutions have been trimming even as the company grew revenue 31%. The disconnect is stark: the market is not convinced that scale translates to earnings recovery.
The bull-bear ledger
Bull: Consolidated revenue 31% YoY (₹580.5 Cr) with domestic 22% and international 15%, both tracking guidance. Standalone margin guidance raised.
Bull: Europe organic growth 40% Q2; U.S. 510k approval in hand, 15+ pending approvals, 10+ in development. Three major European projects go live Q3–Q4.
Bull: Gross margin 70.1% up 111 bps despite raw-material inflation; pricing power evident (4–5% hikes offsetting cost). Renal business 1,250 cumulative machines sold; single-use mandate (DGHS Oct/Nov) to drive demand.
Bear: PAT grew only 3.6% YoY despite 31% revenue growth—margin compression, not scale leverage. Normalized EBITDA 25.3%, dragged by acquisitions at 4–5% margin (target 20%, 3–5 year path).
Bear: Inventory volatility (Q1 ₹200–300 Cr gains reversed in Q2) and FX/raw-material headwinds expected to persist into H2. Normalized gross margin guidance 68–69%, suggesting margin pressure ahead.
Bear: Middle East geopolitical risk: ~20% of prior revenue lost; ongoing logistics/freight cost inflation. PendraCare particularly exposed; margin recovery deferred to FY28–FY29.
Bear: FII ownership halved in 12 months (11.41% → 5.57%). Stock down 51.75% from ATH despite 31% revenue growth—market pricing in execution risk on margin recovery.
Risks, ranked by how much they should concern a holder
Margin recovery timeline extended; acquisition integration slower than expected
HighPendraCare/Citieffe at 4–5% EBITDA vs 20% target, now explicitly 3–5 years out. PAT growth lagging revenue suggests cost structure headwinds deeper than anticipated. Execution risk on margin expansion is the key debate.
Geopolitical: Middle East ~20% of prior revenue; West Asia war driving freight/logistics cost inflation
HighDirect P&L hit from lost revenue, plus ongoing material cost pressures. Pricing hikes (4–5%) only partially offsetting. Normalization timeline uncertain; could extend into FY28.
Inventory and cost structure volatility; normalized margin lower than historical
MediumQ1 ₹200–300 Cr inventory gains reversed in Q2, depressing PAT 3.6%. Normalized EBITDA ~25.3%; management expects gross margin 68–69% full year vs prior ~70%+. Suggests structural margin pressure (FX, raw materials) not fully reversible.
Chinese dumping and renal anti-dumping case outcome uncertain
MediumRenal growing 20% despite competition, but case relief timeline vague ('few months'). DGHS single-use device mandate (Oct/Nov) expected to help, but enforcement and impact timing unclear.
U.S. business: policy uncertainty post-election; 3–5 year path ambitious
MediumTarget ₹15–25m (3–5 years) from ₹7m current. 510k approval in hand, but 15+ pending and 10+ in development. New tariff/approval risks post-election. Management deferred clarity to next quarter.
FII exit continuing; stock down 51% from ATH despite revenue growth
Low-MediumForeign institutions have halved holdings. Suggests market pricing in margin recovery risk or valuation rerating. Stock may find support at lower levels if execution falters further.
The debate
What to watch next
1 · Q3 FY27 EBITDA margin and PAT growth
Can Poly deliver normalized EBITDA margins of 26–27% standalone (vs 25.3% Q2) without inventory one-offs? PAT growth should accelerate above 3.6% if cost normalization is real. This is the acid test for the margin recovery narrative.
2 · European project ramp and new customer quality
Management booked three European projects (Q1, Q4 FY27, Q1 FY28 go-live). Visibility and profitability of these contracts will show whether 40% Q2 growth is sustainable or inventory-driven. New customer count (28–29 added in H1) should translate to recurring revenue.
3 · Geopolitical relief or persistence; freight cost normalization
Middle East revenue recovery timeline and freight cost trends will signal whether H2 margin recovery is achievable. Management expects normalization by H2 FY27; verify in Q3 guidance and commentary.
The number to track
From Q3 onwards, watch standalone EBITDA margin. It is the true test of Poly's operational execution. If it lands at 26–27% as guided, the margin recovery narrative holds and the FY28 upside begins. If it stalls below 25%, cost headwinds are deeper and the acquisition drag will take longer to shed. That single metric—not revenue, not PAT—will resolve whether Poly is a margin-recovery play or a mark-to-market surprise waiting to happen.
Poly Medicure is a steady executor with real international scale and positioning. But this quarter is not a step-change; it is a stress-test on execution. Revenue is strong, but profit is lagging—and the market has already penalized the stock for the margin recovery risk. Standalone EBITDA guidance raised (to 26–27.5%) is the lone bright spot; if FY28 delivers on that promise, the 51% drawdown will look prescient. If not, margin recovery will slide further into FY29–FY30, and valuation has little margin for disappointment.
Revenue surging, profit stumbling—margin recovery is the test
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B+
Domestic growth 22%, international 15% on track. Standalone EBITDA margin guidance raised 26%–27.5%. Revenue run-rate suggests FY27 target achievable; PAT lagging signals execution risk.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong consolidated revenue growth (31% YoY) and international expansion momentum corroborate the long-term expansion thesis. However, PAT growth of only 3.6% YoY despite 30.8% revenue growth reveals material margin compression from cost and FX headwinds, plus acquisition integration drag that management now targets for 3–5 year recovery. Valuation likely prices in the growth story; near-term margin recovery is the execution test.
₹580.5 Cr
Revenue · +30.8% YoY₹95.1 Cr
Reported PAT · +3.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Europe business organic growth 40% in Q2
METQ2 European revenue grew close to 40% organically, per management; still integrating inventory normalization post-prior-year challenges
Domestic business growing 22% in Q2, tracking 20% guidance
METDelivered: domestic Q2 revenue growing 22%, H1 domestic near 20%; on track with stated guidance of >20%
Gross margin 70.1% in H1, expanding 111 bps YoY
METGross margin 70.1% in H1 consolidated, up 111 bps; strong pricing and acquisition contribution, mitigated by FX and raw-material headwinds
Renal business recovering well despite Chinese dumping
OVERSTATEDRenal Q2 revenue ₹51 Cr, up 20% YoY; but management notes ongoing dumping pressure, anti-dumping case filed, awaiting government relief
PAT growth tracking revenue growth
MISSPAT +3.6% YoY vs revenue +30.8%; margin compression from inventory reversal (Q1 gains lost in Q2), cost pressures, forex, acquisition drag
Earnings quality
What changed since the last call
Standalone EBITDA margin guidance raised
UpgradeRaised from 25%–27% to 26%–27.5% on improved performance and pricing actions. Consolidated maintained at 23%–25% due to acquisition drag.
International business inflection confirmed
UpgradeEurope organic growth 40% Q2 vs 10% Q1; international now 15% YoY (Q2 alone), within guidance. Q1 was 10% due to inventory normalization.
Acquired business margin timeline extended
DowngradePendraCare 12% margin target now pushed to mid-teens recovery in FY28 (was expected to recover faster in H1 FY27). Citieffe 14%–15% vs target 20%, 3–5 year path.
U.S. business now multi-year build-out
UpgradeNew quantified target: ₹15–25m over 3–5 years (from vague earlier). 510k approval in hand, 15+ in pipeline, 10+ more pending. Clinical traction building.
FX/raw material headwind expected to persist near-term
DowngradeManagement expects margin normalization only in H2 FY27. Pricing hikes (4%–5%) are offsetting but not fully mitigating cost inflation.
The Q&A
Q&A was substantive; analysts probed Europe growth sustainability, PendraCare margin recovery, and U.S. policy risks. Management held firm on growth narrative but hedged on specific timelines (e.g., PendraCare margin recovery, U.S. approvals post-election). Tender values in Europe dodged ('could be billions'). Overall: confident, not defensive, but selective on granular commitments.
Europe organic growth sustainability — Sidharth Negandhi, CWC
Answered40% driven by inventory normalization in prior year, deeper customer engagement, 28–29 new customers added H1. Management notes opportunity set in Europe is very large. Expected to continue but at more normalized rates H2.
China dumping impact and renal outlook — Sidharth Negandhi, CWC
AnsweredRenal growing 20% Q2 despite dumping pressure. Anti-dumping case filed end-June, 4 months pursued with government, expecting action soon. Government notification issued (DGHS circular Oct/Nov) on single-use devices, which Poly frames as tailwind for demand.
PendraCare margin recovery timeline — Bhavesh Jain, DV Investment Advisors
PartialExpect margin recovery to begin FY28 with projects coming online Q1 CY2027, large OEM partnership benefit. 3–5 year horizon to reach mid-teen targets. Integration with cost-saving synergies ongoing.
European tender market size — Sriram Palaniappan, Cititech
DodgedHimannshu said: 'it could be billions'—very broad estimate. Noted different procurement processes (GPOs, tenders, direct contracts); TAM could exceed few billion dollars.
Q1 vs Q2 margin compression — Simran Thakkar, Beas Capital
AnsweredQ1 margins expanded 2 things: price hikes and low-cost inventory carried from Q4. Q2 saw inventory gains reverse. Normalized gross margin around 68%–69%, historical trend. Full-year guidance 68%–69%.
U.S. business outlook and policy uncertainty — Simran Thakkar, Beas Capital
PartialToo early to assess impact of policy changes. Have USD 7m guidance for current year. Over 3–5 years, targeting ₹15–25m with pipeline of 15+ approvals already, 10+ more pending. Projects in development; will clarify impact next quarter.
Debt and lease liability trends — Rashmmi Shetty, Dolat Capital
AnsweredShort-term debt increase driven by working capital growth with business expansion. No structural change; proportional to growth. Lease liability IFRS 16 accounting treatment started FY27 for subsidiary, now expensed. Long-term debt repayment on Italy subsidiary: USD 6–7m over next 5 years.
Renal dialysis competition and anti-dumping relief — Jasdeep Walia, Clockvine Capital
AnsweredAnti-dumping case filed, government now moving on action (DGHS notification issued). Once implemented, forced single-use devices will increase Poly demand. Competition still present but relief expected. Overseas renal expansion timeline: 12–18 months for registrations.
Acquired business margin recovery timeline and capex — Ashish Sethi, UTI Asset Management
Partial3–5 year path for acquired businesses to 20% EBITDA through synergies, scale, new products. Current capex INR 200–225 Cr annual; targeting 2x revenue by FY30 (from current run-rate). Distributed across plants, ortho/cardiology expansion, U.S./Brazil setup.
Infusion business contribution and new verticals — Ashish Sethi, UTI Asset Management
AnsweredInfusion expected to be 45%–50% of revenue over 4–5 years (currently lower contribution). New verticals: U.S. renal/infusion-driven, Brazil ramp, U.K. direct presence. 30 new product registrations coming in India alone.
Guidance
Consolidated FY27 ₹2,300–2,400 Cr (maintained)
HighH1 already ₹1,106 Cr (organic 14% excl. acquisition impact); run-rate suggests ₹2,212–2,400 Cr achievable; announced annualized guidance confirmed.
Standalone FY27 ₹1,900–1,950 Cr with domestic >20%, international >15%
HighH1 standalone ₹919 Cr; domestic 20% (H1), international 12.5% (H1); Q2 shows domestic 22%, international 15%, suggesting full-year tracking upper end.
U.S. business ₹7m current; ₹15–25m target over 3–5 years
MediumNew quantified multi-year target. 510k approval in hand, 15+ pending approvals, 10+ in development. Policy uncertainty post-election introduces timing risk.
Standalone EBITDA margin 26%–27.5% FY27 (raised from 25%–27%)
HighQ2 standalone EBITDA margin ~27.4% per transcript; pricing hikes offsetting raw-material inflation; inventory normalization complete Q2.
Consolidated EBITDA margin 23%–25% FY27 (maintained)
HighH1 consolidated EBITDA ~24%; acquisition drag (PendraCare/Citieffe at 4%–5%) pulling down consolidated vs standalone. On track.
Gross margin 68%–69% full year (normalized)
MediumH1 actual 71.7% includes inventory gains and acquisition mix benefit; management expects normalization to 68%–69% as inventory effects wash out and raw-material pressure persists near-term.
FY27 capex ₹200–225 Cr (maintained)
HighH1 capex ₹124 Cr; split India ₹124 Cr, overseas ₹15 Cr. Targeting 2x revenue by FY30; capex distributed across infusion, ortho, renal capacity expansion, Brazil/U.K. setup.
Risks the call surfaced
Geopolitical & macro
HighMiddle East was ~20% of revenue in FY26; losses materialized in FY27. Ongoing logistics costs and demand uncertainty in region. Freight cost inflation affecting gross margins.
Acquisition integration
HighPendraCare at 4%–5% EBITDA, previously 10%–12%; target 20% EBITDA margin in 3–5 years. Citieffe at 14%–15% vs target 20%. Geopolitical headwinds (Middle East exposure ~20% of PendraCare) and raw-material costs driving losses. Timeline extends into FY28–FY29.
Product competition & regulation
MediumRenal business faces persistent Chinese competition and dumping pressure. Anti-dumping case filed end-June; status uncertain. Government relief depends on implementation of DGHS single-use device mandate (issued Oct/Nov, enforcement timeline vague).
U.S. market execution & policy
MediumU.S. business targeting ₹7m current, ₹15–25m over 3–5 years. Policy post-election uncertainty (tariffs, approvals). 510k approval in hand, 15+ pending, 10+ in development. Timeline risk if policies change.
Margin pressure and cost structure
MediumQ1 saw ₹200–300 Cr inventory gain that reversed in Q2, depressing PAT growth to 3.6% despite 30.8% revenue growth. Raw-material cost inflation and FX headwinds persist. Pricing hikes (4%–5%) are offsetting but not fully mitigating. Normalized gross margin expected 68%–69% (vs H1 actual 71.7%).
Management
Score 7/10. Clear on strategy and growth drivers (expansion, acquisitions, new products). Transparent on headwinds (FX, raw-material costs, geopolitical). Selective on specifics (tender values in Europe dodged, U.S. policy deferred to next quarter). Strong track record on revenue growth (30%+ YoY). PAT growth lagging (3.6% YoY) due to cost/FX pressures and acquisition drag, suggesting execution challenges on margin recovery. Guidance raised for margins (standalone EBITDA), signaling confidence but yet to be proven.
1 · Q3 FY27
European new projects go live (3 projects in pipeline); IVL minimally-invasive technology launch driving cardiology segment
2 · Q4 FY27
Multiple product registrations (30+ noted) and U.S. approvals kicking in; Brazil operations scaling from October start
3 · H1 FY28
Anti-dumping case resolution expected; renal business benefit if tariff relief granted. PendraCare mid-teen margin recovery begins with OEM partnership.
Valuation likely prices in the growth story; near-term margin recovery is the execution test.